Harbour BioMed’s COPD Drug Enters Phase 2 Trials as Windward Bio Doses First Patients
Event summary
- Harbour BioMed’s partner Windward Bio has dosed the first patients in the Phase 2 SIRIUS study of HBM9378/WIN378 for COPD.
- HBM9378/WIN378 is an ultra long-acting anti-TSLP antibody, also in Phase 2/3 trials for asthma.
- Initial Phase 2 data for asthma is expected in the second half of 2026, with Phase 3 trials set to begin in Q4 2026.
- COPD is the third leading cause of death worldwide, with over 3 million patients at high risk of recurrent exacerbations.
The big picture
Harbour BioMed’s expansion into COPD with HBM9378/WIN378 underscores the growing focus on immune-mediated respiratory diseases. The drug’s potential as a first-to-market ultra long-acting anti-TSLP antibody could address a significant unmet need in both asthma and COPD, positioning it as a key player in the respiratory therapeutics market. The strategic partnership with Windward Bio further strengthens Harbour BioMed’s global reach and execution capabilities.
What we're watching
- Clinical Efficacy
- Whether HBM9378/WIN378 can demonstrate superior efficacy in reducing COPD exacerbations compared to existing therapies.
- Regulatory Pathway
- The pace at which Phase 3 trials for asthma and COPD will progress, given the planned initiation in Q4 2026.
- Market Potential
- How the ultra long-acting anti-TSLP antibody could position itself in the competitive landscape of respiratory disease treatments.